WO2011017606A1 - Methods for improving recombinant protein expression - Google Patents
Methods for improving recombinant protein expression Download PDFInfo
- Publication number
- WO2011017606A1 WO2011017606A1 PCT/US2010/044693 US2010044693W WO2011017606A1 WO 2011017606 A1 WO2011017606 A1 WO 2011017606A1 US 2010044693 W US2010044693 W US 2010044693W WO 2011017606 A1 WO2011017606 A1 WO 2011017606A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- codon
- polynucleotide
- host cell
- protein
- wild
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
- C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
- C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
- C12Y105/01—Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
- C12Y105/01003—Dihydrofolate reductase (1.5.1.3)
Definitions
- This invention has practical application in the field of recombinant protein expression in eukaryotic cells by means of increasing selection pressure on a vector thereby increasing vector-associated heterologous protein expression.
- the invention provides a method for increasing heterologous protein expression in a host cell comprising the steps of culturing the host cell comprising a first heterologous polynucleotide sequence encoding the heterologous protein under conditions that allow for protein expression, the first polynucleotide encoded on a vector, the host cell further comprising a second polynucleotide sequence having a protein coding sequence for a selectable marker protein, the second polynucleotide having a sequence modification compared to a wild-type polynucleotide encoding the selectable marker protein, the sequence modification reducing translation efficiency of mRNA encoded by the second polynucleotide, the second polynucleotide having the sequence modification and the wild-type polynucleotide encoding identical amino acid sequences for the selectable marker protein.
- first polynucleotide and the second polynucleotide are in a single vector, and in one embodiment of this aspect, the first polynucleotide and second polynucleotide are each under transcriptional control of distinct promoters. In other aspects, the first polynucleotide and the second polynucleotide are in separate vectors. In yet another aspect, the first polynucleotide and second polynucleotide are under transcriptional control of the same promoter.
- the modification is in an untranslated region of the second polynucleotide encoding the selectable marker protein, and in certain aspects, the modification is in a 5' untranslated region and/or the modification is in a 3' untranslated region.
- the modification is in a protein coding region of the gene encoding the selectable marker protein.
- the modification is within 25, 20, 15, 10, or 5 codons of an initiating codon of the protein coding region for the selectable marker gene coding sequence.
- the protein coding sequence in the second polynucleotide sequence comprises at least one modified codon that is not a wild-type codon in a wild-type polynucleotide encoding the selectable marker protein, the modified codon being a codon that is not a preferred codon for the encoded amino acid for the host cell.
- the protein coding sequence in the second polynucleotide sequence comprises at least one modified codon that is not a wild-type codon in a wild-type polynucleotide encoding the selectable marker protein, the modified codon being a codon that is a least preferred codon for the encoded amino acid for the host cell.
- the protein coding sequence in the second polynucleotide sequence comprises at least one modified codon that is not a wild-type codon in a wild-type polynucleotide encoding the selectable marker protein, and the modification introduces a change in secondary structure of the mRNA which reduces translation efficiency of the mRNA.
- the protein coding sequence in the second polynucleotide sequence comprises at least one modified codon that is not a wild-type codon in a wild-type polynucleotide encoding the selectable marker protein, and the modification increases codon pairing in the mRNA.
- the protein coding sequence in the second polynucleotide sequence comprises at least one modified codon that is not a wild-type codon in a wild-type polynucleotide encoding the selectable marker protein, and the modification modifies G+C content of the mRNA
- the modification increases G+C content of the mRNA
- the G+C content is increased by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58 ,59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80,
- the protein coding sequence in the second polynucleotide sequence comprises at least one modified codon that is not a wild-type codon in a wild-type polynucleotide encoding the selectable marker protein, and the modification modifies A+T content of the mRNA.
- the modification decreases A+T content of the mRNA, and in certain aspects, the A+T content is decreased by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58 ,59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%.
- the selectable marker protein is selected from the group consisiting of neomycin phosphotransferase (npt II), hygromycin
- hpt phosphotransferase
- dhfr dihydrofoate reductase
- zeocin phleomycin
- bleomycin resistance gene ble gentamycin acetyltransferase
- streptomycin phosphotransferase mutant form of acetolactate synthase (als), bromoxynil nitrilase, phosphinothricin acetyl transferase (bar), enolpyruvylshikimate-3- ⁇ phosphate (EPSP) synthase (aro A), muscle specific tyrosine kinase receptor molecule (MuSK-R), copper-zinc superoxide dismutase (sodl),
- metallothioneins cupl, MTl
- beta-lactamase BLA
- puromycin N- acetyl-transferase pac
- blasticidin acetyl transferase bis
- blasticidin deaminase bsr
- histidinol dehydrogenase HDH
- SAICAR N-succinyl-5-aminoimidazole-4-carboxamide ribotide
- SAICAR synthetase
- arg4 argininosuccinate lyase
- beta-isopropylmalate dehydrogenase Ieu2
- invertase suc2
- OMP orthologs of any of these marker proteins.
- the host cell is a eukaryotic cell, the host cell is a mammalian cell, the host cell is a human cell, the host cell is a Chinese hamster cell, the host cell is a Chinese hamster ovary cell, the host cell is a yeast cell, the host cell is
- the host cell is a Pichia pastoris cell, the host cell is a prokaryotic cell, the host cell is an Escherichia coli cell, the host cell is an insect cell, the host cell is a Spodoptera frugiperda cell, the host cell is a plant cell, or the host cell is a fungal cell.
- the expression vector is a (Chinese hamster elongation factor 1 (CHEFl) expression vector.
- the method utilizes a second polynucleotide which comprises the polynucleotide set out in Figure 2, and in one
- the second polynucleotide comprises the polynucleotide set out in Figure 2 in a (Chinese hamster elongation factor 1 (CHEFl) expression vector.
- CHEFl Choinese hamster elongation factor 1
- Figure IA is a DHFR-encoding polynucleotide and Figure IB is a DHFR polypeptide sequence used for codon deoptimization identical to Mus musculus cDNA BC005796.
- Figure 2 shows DNA sequences of the codon deoptimized DHFR sequences designated crippled (cr) and worst (wst).
- Figure 3 shows deoptimized DHFR (worst, wst and crippled, cr) aligned with wild type (wt) sequence. Nucleotide changes (*) including hamster least preferred codons (see Table 4) and new tandem codon pairs (in bold; see Table 5) are indicated. Degenerate symbols are: B (C or G or T), D (A or G or T), H ( A or C or T), V (A or C or G).
- Figure 4 shows the CHEFl expression vector, pDEF38, with wild type (WT) DHFR.
- Codon deoptimized DHFR replaces WT DHFR to make pDEF81 (crippled DHFR) and pDEF82 (worst DHFR).
- the reporter gene FIGI is cloned into the Xhol - Xbal cloning sites to make pDEF38:FIGI, pDEF81:FIGI and pDEF82:FIGI.
- Figure 5 shows that protein expression increases using codon deoptimized DHFR.
- CHO cells were transfected with wild type (wt) and codon deoptimized (crippled, pDEF ⁇ l :FIGI and worst, pDEF82:FIGI) DHFR coexpressing a protein of interest (FIGI).
- Titer values determined by protein A HPLC and reported in ⁇ g/ml are averages of two independent transfections, each measured in triplicate (six total production assays). The results indicate a clear improvement in expression titer for the codon deoptimized DHFR selected transfection pools over the wild type DHFR pools.
- FIG. 6 demonstrates that a transfection pool fed-batch production model provides improved productivity in codon deoptimized cell lines.
- This experiment was carried out for 12 days in 50 ml spin tubes with pooled transfectants; wild type (pDEF38:FIGI, blue) and codon deoptimized (pDEF81 :FIGI, purple and pDEF82:FIGI, pink) DHFR coexpressing the protein of interest FIGI.
- Two transfection pools (A and B) were done in duplicate. The codon deoptimized pools show greater productivity than the wild type samples.
- Figure 7 shows that codon deoptimized DHFR selected cells have reduced DHFR and increased protein of interest expression.
- CHO cells were transfected with wild type (T462) and codon deoptimized (pDEF81 :FIGI, T463 and pDEF82:FIGI, T464) DHFR coexpressing the protein of interest FIGI.
- Transfection pools were stained with both fluorescent methotrexate (F-MTX) to detect DHFR and a fluorescent labeled antibody that recognizes FIGI (RPE). Stained cells were analyzed by flow cytometry on the FACSCalibur.
- Figure 7 A shows dual stain FACS profiles of 10,000 individual cells from each transfection plotting combined DHFR (F-MTX) and FIGI (RPE:FIGI) expression.
- Figure 7B shows mean F-MTX (DHFR) and RPE fluorescence intensity from two populations of 10,000 cells averaged for each transfection. These results indicate that both codon deoptimized DHFR pools have reduced DHFR and increased FIGI production when compared to wild type cells.
- Figure 8 demonstrates that codon deoptimized DHFR clones have reduced DHFR and increased protein of interest expression.
- CHO cell transfection pools wild type T462, crippled T463 and worst T464 were cloned by limiting dilution and 23 confirmed monoclonal cell lines were expanded from each transfection.
- Clonal cells were stained with both fluorescent methotrexate (DHFR RFU) to detect DHFR and the RPE labeled anti-F ⁇ GI fluorescent antibody (FIGI RFU). A total of 10,000 stained cells from each clonal population were analyzed by flow cytometry on the FACSCalibur.
- Figure 8A shows mean fluorescence of F-MTX stained cells. Each data point is an individual clone. Clones are ranked from low to high mean fluorescence.
- Figure 8B shows mean fluorescence of RPE stained cells. Each data point is an individual clone. Clones are ranked from low to high mean fluorescence.
- Figure 9 shows that codon deoptimized clones have improved productivity compared to wild type clones.
- Clone titers were determined by Protein A HPLC on Day 8 harvest supernatants from 6-well production models. Clones are ranked by titer from high to low.
- the codon deoptimized clones, pDEF81 :FIGI and pDEF82:FIGI, show greater FIGI productivity than the wild type DHFR clones (pDEF38:FIGI).
- the present invention provides a new generation of expression vectors and uses thereof, that improve recombinant protein yields.
- the vectors of the invention allow for increased expression of a gene of interest (GOI) in a host cell and reduce translation efficiency of a co-transformed selectable marker, thereby increasing selection stringency.
- Selectable markers are used in transfection experiments to complement host cell protein deficiencies or confer resistance to an otherwise toxic agent, and thereby select for the presence (expression) of co-transformed genes of interest.
- the vectors that provide for reduced translation efficiency of the selection marker protein are designed such that the polynucleotide encoding the selction marker protein are "deoptimized" with respect to one or more parameters.
- modifying a polynucleotide encoding a selectable marker gene sequence to be less than optimal for translation, regardless of making similar changes in the gene of interest, allows for isolation of host cells transformed or transfected with a polynucleoptide encoding a GOI and a polynucleotide encoding a selectable marker wherein the protein encoded by the GOI is expressed at unexpectedly high levels.
- the term "deoptimized" as used herein with reference to a polynucleotide means that the polynucleotide has been modified in such a way that translation of a protein encoded by the polyncleotide is less than optimal for the host cell in which the polyncleotide has been introduced.
- a polynucleotide is deoptimized in a multitude of ways and the present invention is not limited by the methods exemplified herein.
- the vectors and methods of the invention are amenable for use with any selectable marker gene that provides positive selection.
- selectable markers include, without limitation antibiotic resistance genes encoding neomycin phosphotransferase (npt II), hygromycin phosphotransferase (hpt), dihydrofoate reductase (dhfr), zeocin, phleomycin, bleomycin resistance gene ble (enzyme not known), gentamycin acetyltransferase, streptomycin phosphotransferase, mutant form of acetolactate synthase (als), bromoxynil nitrilase, phosphinothricin acetyl transferase (bar), enolpyruvylshikimate-3-phosphate (EPSP) synthase (aro A), muscle specific tyrosine kinase receptor molecule (MuSK-R), copper-zinc superoxide dis
- the genetic code sets out codons that direct addition of specific amino acids in a translated polypeptide.
- the twenty naturally-occurring amino acids are encoded by different numbers of codons, ranging from one to six different codons for each amino acid.
- different codons that encode the same amino acid are referred to as "synonymous codons.” These synonymous codons are set out below in Table 1.
- GTT VaI V
- GCT AIa A
- GAT Asp D
- GAT GIy G
- GTA VaI V
- GCA Ala A
- GAA GIu E
- GGA GIy G
- synonymous codons encode the same animo acid
- altering the coding sequence of a protein by replacing a wild-type codon with a synonymous codon does not change the amino acid sequence of the encoded polypeptide sequence.
- sequence of the underlying mRNA encoding the protein is altered and the change in the mRNA nucleotide sequence can alter gene expression by influencing translational efficiency (Ikemura 1981a, Ikemura 1981b, Ikemura 1985).
- the invention provides vectors and methods to increase expression of a recombinant protein encoded by a GOI, utilizing an expression vector comprising the GOI and also encoding a selectable marker protein in a synthetic polynucleotide designed with codons that are not preferred in the host cell. It is well known in the art that in different species, certain synomymous codons are more frequently utilized than others. Those codons that are most frequently utilized are referred to a "preferred codon" for that species.
- codons preference for certain codons is a function of the relative number of specific transfer RNAs (tRNA) encoded in a species genome, and programs have been developed to determine the precise number of each tRNA encoded in a specific genome (Lowe and Eddy, 1997). Thus in one aspect, selection of less than preferred codons is based on previously determined utilization frequency of synonymous codons in a particular host cell species of origin.
- tRNA transfer RNAs
- the invention provides a polynucleotide encoding a selectable marker wherein the protein coding region of the polynucleotide includes at least one codon modification, the modification being replacement of a wild-type codon with a codon that is not a preferred codon for the host cell.
- the modification is replacement of a wild-type codon with a codon that is a least preferred codon for the host cell. Any number of such codon replacements is contemplated as long as a least one such modification is incorporated in the protein coding region. Accordingly, the invention contemplated anywhere from one such modified codon to modification of all codons in the protein ccoding region of the selectable marker gene.
- codons are used to preferentially replace synonymous codons in a native gene sequence encoding a marker gene such that at least one to all of the synonymous codons are replaced with any codon that is not the preferred codon for a specific amino acid residue.
- Table 2. Hamster Codon Usage Table
- codon usage table from Hamster (Cricetulus griseus) from 331 protein coding regions and 153527 codons. For each codon, the first number is the frequency per thousand and the second number is the actual number of times that codon was observed.
- UUU 19.6 3005) UCU 16.0 ( 2450) UAU 13.1 ⁇ 2017) UGU 9.1 ( 1397)
- codon usage table from Human ⁇ Homo sapiens
- the first number is the frequency per thousand and the second number is the actual number of times that codon was observed.
- UUU 17.6 (714298) UCU 15.2 (618711) UAU 12.2 (495699) UGU 10.6 (430311)
- AUC 20.8 (846466) ACC 18.9(768147) AAC 19.1(776603) AGC 19.5 (791383)
- Codon deoptimization can be carried out by a variety of methods, for example, by selecting codons which are less than preferred for use in highly expressed genes in a given host cell.
- Computer algorithms which incorporate codon frequency tables such as
- codon preference of highly expressed bacterial genes may be used and are provided by the University of Wisconsin Package Version 9.0, Genetics Computer Group, Madison, WI.
- Other useful codon frequency tables include “Celegans high. cod”,
- the invention provides vectors and methods to increase expression of a recombinant protein encoded by a transfected GOI, utilizing an expression vector encoding a selectable marker protein in a synthetic polynucleotide designed with codon pairs that are least favored in the host cell species of origin.
- a selectable marker protein in a synthetic polynucleotide designed with codon pairs that are least favored in the host cell species of origin.
- the Ala codon GCC is used four times as frequently as the synonymous codon GCG and that other synonymous codon pairs are used more or less frequently than expected (Coleman et al., 2008). This frequency of specific codon pairs is referred to as the "codon pair bias.”
- the amino acid pair Ala-Glu is expected to be encoded by GCCGAA and GCAGAG about equally often.
- the codon pair GCCGAA is strongly underrepresented, even though it contains the most frequent Ala codon, such that it is used only one-seventh as often as GCAGAG.
- the invention provides vectors and methods to increase expression of a recombinant protein encoded by a GOT, utilizing an expression vector comprising the GOI and also encoding a selectable marker protein in a synthetic
- polynucleotide designed with tandem codon pairing The frequency and composition of codon pairs in a gene sequence can influence the rate of translation as evidenced by attenuation (Watson 1988) and translational frame shifiting (Gurvich et al., 2005).
- the mechanism of attenuation involves the pausing of ribosomes at tandem pairs or multimeric repeats of the same codon and is influenced by the codon-specified activated tRNA concentration.
- rare codons are paired the paucity of cognate tRNA molecules can lead to not only pausing, but frameshifting, resulting in a reduction of accurately translated protein. Both of these tandem codon pairing mechanisms of action could be utilized to deoptimize expression of a selectable marker gene.
- Codons are all least preferred except those in bold
- repeated amino acid residues in tandem in the selectable marker protein wherein the same amino acid is present in more than one copy in the primary structure in tandem, are encoded by codons that are not a preferred codon for that amino acid.
- repeated amino acid residues in tandem in the selectable marker protein, wherein the same amino acid is present in more than one copy in the primary structure in tandem are encoded by codons that are the least preferred eodons for that amino acid.
- the same amino acids present in more than one copy and in tandem in the primary structure are encoded by the same codon.
- the invention provides methods to increase expression of a recombinant protein encoded by a GOI, utilizing an expression vector encoding a selectable marker protein in a polynucleotide designed with sequence modifications that alter RNA secondary structure.
- the structure of the mRNA is considered when designing a gene for codon deoptimization.
- the sequence context of, for example, the redesigned codons can modulate RNA secondary structure which has been shown to regulate the stability and translatability of the mRNA message (Griswold 2003, Kozak 2005, Kudla 2009).
- Factors to consider in designing a codon deoptimized selectable marker include, but are not limited to, secondary structure stability and minimum free energy (MFE) of the entire or 5' end of the RNA, as can be determined by open access RNA structure prediction software like RNAfold (Gruber et al, 2008).
- MFE minimum free energy
- Sequence context of the deoptimized gene in regions surrounding, or in part of a least preferred codon may also be important.
- Factors that may reduce translational efficiency include GC content, G+C in the codon third postion (Sueoka and Kawanishi, 2000), and codon adaptation index scores (Sharp and Li, 1987). Indeed, evidence has shown that higher GC content in mRNA increases the likelihood of secondary structure formation that will hamper translation efficiency, and that reducing GC content destabilizes these secondary structures (Bulmer, 1989).
- mRNA 5' noncoding region modulate translational efficiency; translational efficiency has been shown to be inversely proportional to the degree of secondary structure at the mRNA 5' noncoding region. (Pelletier and Sonenberg, 1987).
- a method is provided wherein the polynucleotide encoding the selectable marker protein is modified outside of the the context of the protein coding region, and modifications to the gene are made such that untranslated regions of the encoded mRNA have increased secondary structure compared to the wild-type mRNA.
- one or more modifications is introduced in a 5' and/or 3' untranslated region that is not necessary for translation.
- the modification or modifications are introduced in a 5' and/or 3' region that is necessary for translation.
- Any eukaryotic and prokaryotic vector is contemplated for use in the instant methods, including mammalian, yeast, fungal, insect, plant or viral vectors useful for selected host cell.
- vector is used as recognized in the art to refer to any molecule (e.g., nucleic acid, plasmid, or virus) used to transfer coding information to a host cell.
- host cell is used to refer to a cell which has been transformed, or is capable of being transformed, by a vector bearing a selected gene of interest which is then expressed by the cell.
- the term includes mammalian, yeast, fungal, insect, plant and protozoan cells, and the progeny of the parent cell, regardless of whether the progeny is identical in morphology or in genetic make-up to the original parent, so long as the selected gene is present.
- any vector can be used in methods of the invention and selection of an appropriate vector is, in one aspect, based on the host cell selected for expression of the GOI.
- Examples include, but are not limited to, mammalian cells, such as Chinese hamster ovary cells (CHO) (ATCC No. CCL61); CHO DHFR-cells, human embryonic kidney (HEK) 293 or 293T cells (ATCC No. CRLl 573); or 3T3 cells (ATCC No. CCL92).
- mammalian cells such as Chinese hamster ovary cells (CHO) (ATCC No. CCL61); CHO DHFR-cells, human embryonic kidney (HEK) 293 or 293T cells (ATCC No. CRLl 573); or 3T3 cells (ATCC No. CCL92).
- CHO Chinese hamster ovary cells
- HEK human embryonic kidney
- CRLl 573 ATCC No. CRLl 573
- 3T3 cells ATCC No. CCL92
- Other suitable mammalian cell lines are the monkey COS-I (ATCC No. CRLl 650) and COS-7 (ATCC No. CRL165
- mammalian cell lines include, but are not limited to, Sp2/0, NSl and NSO mouse hybridoma cells, mouse neuroblastoma N2A cells, HeLa, mouse L-929 cells, 3T3 lines derived from Swiss, Balb-c or NIH mice, BHK or HaK hamster cell lines, which are also available from the ATCC.
- mammalian host cells include primate cell lines and rodent cell lines, including transformed cell lines. Normal diploid cells, cell strains derived from in vitro culture of primary tissue, as well as primary explants, are also suitable.
- E. coli e.g., HBlOl, (ATCC No. 33694) DH5y, DHlO, and MC1061 (ATCC No. 53338)
- various strains of B. subtilis Pseudomonas spp., Streptomyces spp., Salmonella typhimurium and the like.
- yeast cells known to those skilled in the art are also available as host cells for expression of a GOI and include, for example, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains, Candida, Pichia ciferrii and Pichia pas tor is.
- insect cell systems may be utilized in the methods of the present invention.
- Such systems include for example and without limitation, Sf-9 and Hi5 (Invitrogen, Carlsbad, CA).
- Exemplary fungal cells include, without limitation, Thermoascus aurantiaciis, Aspergillus ⁇ ax ⁇ Qntous fungus), including without limitation Aspergillus oryzaem,
- Exemplary protozoan cells include without limitation Tetrahymena strains and Trypanosoma strains.
- the present invention is exemplified using least-preferred hamster codons to generate a codon deoptimized DHFR (CDD) encoding-gene suitable for selection in Chinese hamster ovary (CHO) cells.
- CDD codon deoptimized DHFR
- the starting gene was identical to a Mus musculus DHFR-encoding cDNA, Accession Number BC005796 and encodes the wild type DHFR polypeptide (See Figure 1).
- Two versions of a codon deoptimized DHFR-encoding polynucleotide were synthesized, designated herein as crippled and worst, representing intermediate- and maximally- deoptimized coding sequences, respectively. These polynucletoides were designed using a GENEART AG CHO codon usage algorithm. The codon deoptimized DHFR-encoding polynucleotide sequences are shown in Figure 2.
- the codon deoptimized DHFR genes are aligned with the wild type DHFR gene sequence in Figure 3 and highlight the nucleotide differences resulting from the introduction of hamster least preferred codons and tandem codon pairs. The translation products for all three genes, wild type, crippled and worst, are identical.
- the codon deoptimized DHFR-encoding polynucleotide sequences were introduced into expression vector pDEF38, a CHEFl expression vector (US Patent No. 5,888,809), to replace the wild type DHFR encoding sequence ( Figure 4).
- the resultant plasmids were named pDEF81 (crippled DHFR) and pDEF82 (worst DHFR).
- FIGI The reporter gene of interest, FIGI, encoding an IgGl Fc fusion protein, was cloned into the multiple cloning site (Xhol to Xbal) of pDEF38, pDEF81 and pDEF82 to create the expression vectors pDEF38:FIGI, pDEF81 :FIGI and pDEF82:FIGI, respectively.
- FIGI expression vectors were transfected into CHO DG44 cells, grown for two days in non-selection media containing hypoxanthine and thymidine (HT), then selected in media lacking HT (-HT). The selected cell populations, or pools, were expanded and split into production model cultures to assess productivity.
- HT hypoxanthine and thymidine
- Transfection pools were diluted to seed single cells into individual wells of 96well plates. The plates were imaged with the Clone Select Imager (Genetix) and wells containing FIGI-expressing cells derived from a single cell were expanded. Twenty three clones were randomly selected from the limiting dilution plates for each transfection (wild type, crippled and worst DHFR) from the confirmed monoclonal sets.
- the 6-well production models were inoculated with a total of one million cells into 3 ml of cell culture media with 10% FBS and grown for 4 days at 37 0 C, then 4 days at 34 0 C.
- Harvest supernatants were filtered through 0.2 micrometer filters and assayed for FIGI production by Protein A HPLC.
- Fed batch production models were seeded at 0.5 million cells/mL in culture media supplemented with 10% FBS in spin tubes.
- the 5OmL spin tubes were run with a working volume of 15mL. After seeding, samples were grown at 37°C and 6% CO 2 for 3 days, with feeding and temperature shift to 34°C beginning on day 4. Samples for titer and cell densities were collected on days 3, 5, 7, 10 and 12. The study was concluded on day 12.
- FACS analysis was performed with Day 2 normal growing cells that were harvested and stained with fluorescein isothiocyanate labeled methotrexate (F-MTX) to detect DHFR protein and an R-Phycoeythrin (RPE) labeled anti-IgGl Fc to detect FIGI.
- F-MTX fluorescein isothiocyanate labeled methotrexate
- RPE R-Phycoeythrin
- Stable cell lines expressing the reporter protein FIGI were made using wild type and codon deoptimized genes encoding the DHFR selectable marker.
- Duplicate transfections (T462 - T464, A and B) were performed with the wild type, crippled and worst DHFR plasmids expressing the reporter protein FIGI. The individual colonies counted for each transfection are reported as "Number of Transfectants.”
- the transfection results indicate that the selection pressure is increased when using codon deoptimized DHFR (CDD) as compared to wild type DHFR. This result is seen as a reduction in the number of CDD transfectants selected in media lacking HT.
- CDD codon deoptimized DHFR
- Table 6 The number of transfectants per transfection.
- FIGI protein produced from pooled transfectants in the 6-well, 8 day ( Figure 5) and spin tube, 12 day fed batch ( Figure 6) production models show an unexpected increase in productivity of the GOI with the codon deoptimized DHFR selectable marker gene over the wild type DHFR gene.
- the crippled DHFR gene yielded the highest titer. This result is consistent with the observation that the crippled DHFR selection was the most stringent (See Table 6) and suggests that the diversity in the population may be reduced but the average cell expresses more POI.
- compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of specific embodiments, it will be apparent to those of skill in the art that variations of the compositions and/or methods and in the steps or in the sequence of steps of the method described herein can be made without departing from the concept and scope of the invention. More specifically, it will be apparent that certain polynucleotides which are both chemically and biologically related may be substituted for the polynucleotides described herein while the same or similar results are achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the, scope and concept of the invention as defined by the appended claims.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2771410A CA2771410C (en) | 2009-08-06 | 2010-08-06 | Methods for improving recombinant protein expression comprising reduction in translation efficiency of a selectable marker protein |
CN2010800444750A CN102648285A (en) | 2009-08-06 | 2010-08-06 | Methods for improving recombinant protein expression |
PL10807224T PL2462237T3 (en) | 2009-08-06 | 2010-08-06 | Methods for improving recombinant protein expression |
NZ598275A NZ598275A (en) | 2009-08-06 | 2010-08-06 | Methods for improving recombinant protein expression |
KR1020127005781A KR101800904B1 (en) | 2009-08-06 | 2010-08-06 | Methods for improving recombinant protein expression |
EP10807224.0A EP2462237B1 (en) | 2009-08-06 | 2010-08-06 | Methods for improving recombinant protein expression |
US13/390,297 US9212367B2 (en) | 2009-08-06 | 2010-08-06 | Methods for improving recombinant protein expression |
SI201031140T SI2462237T1 (en) | 2009-08-06 | 2010-08-06 | Methods for improving recombinant protein expression |
ES10807224.0T ES2563073T3 (en) | 2009-08-06 | 2010-08-06 | Methods to improve the expression of recombinant proteins |
AU2010279294A AU2010279294B2 (en) | 2009-08-06 | 2010-08-06 | Methods for improving recombinant protein expression |
DK10807224.0T DK2462237T3 (en) | 2009-08-06 | 2010-08-06 | PROCEDURES FOR IMPROVING RECOMBINANT PROTEIN EXPRESSION |
US14/952,245 US10066231B2 (en) | 2009-08-06 | 2015-11-25 | Methods for improving recombinant protein expression |
HRP20160162TT HRP20160162T1 (en) | 2009-08-06 | 2016-02-15 | Methods for improving recombinant protein expression |
SM201600147T SMT201600147B (en) | 2009-08-06 | 2016-05-27 | METHODS TO IMPROVE THE EXPRESSION OF RECOMBINANT PROTEINS |
US16/117,467 US20190225972A1 (en) | 2009-08-06 | 2018-08-30 | Methods for improving recombinant protein expression |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23190609P | 2009-08-06 | 2009-08-06 | |
US61/231,906 | 2009-08-06 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/390,297 A-371-Of-International US9212367B2 (en) | 2009-08-06 | 2010-08-06 | Methods for improving recombinant protein expression |
US14/952,245 Continuation US10066231B2 (en) | 2009-08-06 | 2015-11-25 | Methods for improving recombinant protein expression |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011017606A1 true WO2011017606A1 (en) | 2011-02-10 |
Family
ID=43544683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/044693 WO2011017606A1 (en) | 2009-08-06 | 2010-08-06 | Methods for improving recombinant protein expression |
Country Status (15)
Country | Link |
---|---|
US (3) | US9212367B2 (en) |
EP (1) | EP2462237B1 (en) |
KR (1) | KR101800904B1 (en) |
CN (1) | CN102648285A (en) |
AU (1) | AU2010279294B2 (en) |
CA (1) | CA2771410C (en) |
DK (1) | DK2462237T3 (en) |
ES (1) | ES2563073T3 (en) |
HR (1) | HRP20160162T1 (en) |
HU (1) | HUE028655T2 (en) |
NZ (1) | NZ598275A (en) |
PL (1) | PL2462237T3 (en) |
SI (1) | SI2462237T1 (en) |
SM (1) | SMT201600147B (en) |
WO (1) | WO2011017606A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011141027A1 (en) * | 2010-05-08 | 2011-11-17 | Kobenhavns Universitet | A METHOD OF STABILIZING mRNA |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110042122A (en) * | 2013-03-12 | 2019-07-23 | Agc生技制品公司 | It is expressed using the improvement recombinant protein of heterozygosis CHEF1 promoter |
KR101446054B1 (en) * | 2013-03-14 | 2014-10-01 | 전남대학교산학협력단 | Translational rate-regulating ramp tag for recombinant protein over- expression and use thereof |
CN107794275B (en) * | 2017-11-06 | 2020-04-21 | 河北省微生物研究所 | Recombinant pichia pastoris for producing (+) gamma-lactamase and construction method and application thereof |
AU2019206443A1 (en) | 2018-01-10 | 2020-07-23 | Cmc Icos Biologics, Inc. | Bidirectional CHEFl vectors |
KR20200082618A (en) | 2018-12-31 | 2020-07-08 | 주식회사 폴루스 | Ramp Tag for Overexpressing Insulin and Method for Producing Insulin Using the Same |
CN111434693B (en) * | 2019-01-11 | 2022-03-08 | 江苏芝大生物科技有限公司 | Antioxidant fusion protein and application thereof |
CN109979539B (en) * | 2019-04-10 | 2020-10-02 | 电子科技大学 | Gene sequence optimization method and device and data processing terminal |
CN112301047A (en) * | 2020-11-02 | 2021-02-02 | 江苏东玄基因科技有限公司 | Method for accurately regulating and controlling recombinant protein expression |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004070030A1 (en) * | 2003-02-03 | 2004-08-19 | Immuno Japan Inc. | Overexpression vector for animal cell |
US20060154369A1 (en) * | 2005-01-10 | 2006-07-13 | Guang-Hsiung Kuo | Promoter sequences from WSSV immediate early genes and their uses in recombinant DNA techniques |
US20080118530A1 (en) * | 2004-10-08 | 2008-05-22 | Kew Olen M | Modulation of Replicative Fitness By Deoptimization of Synonymous Codons |
US20080187953A1 (en) * | 2002-11-29 | 2008-08-07 | Barbara Enenkel | Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product |
US20080293105A1 (en) * | 2004-12-08 | 2008-11-27 | Icos Corporation | Recombinant method for making multimeric proteins |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
ES2088838T3 (en) * | 1992-11-13 | 2004-01-01 | Idec Pharmaceuticals Corporation | FULLY ALTERED KOZAK CONSENSUS SEQUENCES INTENDED FOR EXPRESSION IN THE MAMMALS. |
US5795737A (en) | 1994-09-19 | 1998-08-18 | The General Hospital Corporation | High level expression of proteins |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
US7316925B2 (en) * | 2002-07-16 | 2008-01-08 | Vgx Pharmaceuticals, Inc. | Codon optimized synthetic plasmids |
EP1546329A4 (en) * | 2002-09-13 | 2006-07-12 | Univ Queensland | Gene expression system based on codon translation efficiency |
SI1809750T1 (en) * | 2004-11-08 | 2012-08-31 | Chromagenics Bv | Selection of host cells expressing protein at high levels |
WO2007130606A2 (en) * | 2006-05-04 | 2007-11-15 | The Regents Of The University Of California | Analyzing translational kinetics using graphical displays of translational kinetics values of codon pairs |
-
2010
- 2010-08-06 CN CN2010800444750A patent/CN102648285A/en active Pending
- 2010-08-06 HU HUE10807224A patent/HUE028655T2/en unknown
- 2010-08-06 NZ NZ598275A patent/NZ598275A/en not_active IP Right Cessation
- 2010-08-06 CA CA2771410A patent/CA2771410C/en active Active
- 2010-08-06 AU AU2010279294A patent/AU2010279294B2/en active Active
- 2010-08-06 WO PCT/US2010/044693 patent/WO2011017606A1/en active Application Filing
- 2010-08-06 PL PL10807224T patent/PL2462237T3/en unknown
- 2010-08-06 US US13/390,297 patent/US9212367B2/en active Active
- 2010-08-06 KR KR1020127005781A patent/KR101800904B1/en active IP Right Grant
- 2010-08-06 ES ES10807224.0T patent/ES2563073T3/en active Active
- 2010-08-06 DK DK10807224.0T patent/DK2462237T3/en active
- 2010-08-06 SI SI201031140T patent/SI2462237T1/en unknown
- 2010-08-06 EP EP10807224.0A patent/EP2462237B1/en active Active
-
2015
- 2015-11-25 US US14/952,245 patent/US10066231B2/en active Active
-
2016
- 2016-02-15 HR HRP20160162TT patent/HRP20160162T1/en unknown
- 2016-05-27 SM SM201600147T patent/SMT201600147B/en unknown
-
2018
- 2018-08-30 US US16/117,467 patent/US20190225972A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080187953A1 (en) * | 2002-11-29 | 2008-08-07 | Barbara Enenkel | Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product |
WO2004070030A1 (en) * | 2003-02-03 | 2004-08-19 | Immuno Japan Inc. | Overexpression vector for animal cell |
US20080118530A1 (en) * | 2004-10-08 | 2008-05-22 | Kew Olen M | Modulation of Replicative Fitness By Deoptimization of Synonymous Codons |
US20080293105A1 (en) * | 2004-12-08 | 2008-11-27 | Icos Corporation | Recombinant method for making multimeric proteins |
US20060154369A1 (en) * | 2005-01-10 | 2006-07-13 | Guang-Hsiung Kuo | Promoter sequences from WSSV immediate early genes and their uses in recombinant DNA techniques |
Non-Patent Citations (4)
Title |
---|
MESBAH ET AL.: "Precise Measurement of the G+C Content of Deoxyribonucleic Acid by High- Performance Liquid Chromatography.", INTERN. J SYSTEM CTERIOL., vol. 39, no. 2, 1989, pages 159 - 167, XP008153656 * |
MUELLER ET AL.: "Reduction of the Rate of Poliovirus Protein Synthesis through Large-Scale Codon Deoptimization Causes Attenuation of Viral Virulence by Lowering Specific Infectivity.", J. VIROL., vol. 80, no. 19, 2006, pages 9687 - 9696, XP002633526 * |
See also references of EP2462237A4 * |
WESTWOOD ET AL.: "Improved recombinant protein yield using a codon deoptimized DHFR selectable marker in a CHEF1 expression plasmid.", BIOTECHNOL PROG., 25 August 2010 (2010-08-25), XP055017665 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011141027A1 (en) * | 2010-05-08 | 2011-11-17 | Kobenhavns Universitet | A METHOD OF STABILIZING mRNA |
Also Published As
Publication number | Publication date |
---|---|
US10066231B2 (en) | 2018-09-04 |
SMT201600147B (en) | 2016-07-01 |
HUE028655T2 (en) | 2016-12-28 |
EP2462237B1 (en) | 2015-12-23 |
US20190225972A1 (en) | 2019-07-25 |
HRP20160162T1 (en) | 2016-04-08 |
EP2462237A1 (en) | 2012-06-13 |
KR101800904B1 (en) | 2017-12-20 |
AU2010279294A1 (en) | 2012-03-15 |
ES2563073T3 (en) | 2016-03-10 |
SI2462237T1 (en) | 2016-04-29 |
NZ598275A (en) | 2014-11-28 |
US20160076043A1 (en) | 2016-03-17 |
AU2010279294B2 (en) | 2014-12-04 |
KR20120041245A (en) | 2012-04-30 |
US20120214203A1 (en) | 2012-08-23 |
EP2462237A4 (en) | 2013-07-03 |
US9212367B2 (en) | 2015-12-15 |
CA2771410A1 (en) | 2011-02-10 |
DK2462237T3 (en) | 2016-03-29 |
CN102648285A (en) | 2012-08-22 |
PL2462237T3 (en) | 2016-06-30 |
CA2771410C (en) | 2020-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10066231B2 (en) | Methods for improving recombinant protein expression | |
JP6211577B2 (en) | Products and Methods for Transformation of Trout Chitriales Microorganisms | |
JP5735927B2 (en) | Re-engineering the primary structure of mRNA to enhance protein production | |
US20210340560A1 (en) | Improved recombinant protein expression using a hybrid chef1 promoter | |
Westwood et al. | Improved recombinant protein yield using a codon deoptimized DHFR selectable marker in a CHEF1 expression plasmid | |
O'Neill et al. | Expression of the Synechocystis sp. strain PCC 6803 tRNA (Glu) gene provides tRNA for protein and chlorophyll biosynthesis | |
KR20220150363A (en) | Improved Cytosine Base Editing System | |
US20240124850A1 (en) | Auxotrophic Cells for Virus Production and Compositions and Methods of Making | |
US7138515B2 (en) | Translational activity-promoting higher-order structure | |
JP2015180203A (en) | REENGINEERING mRNA PRIMARY STRUCTURE FOR ENHANCED PROTEIN PRODUCTION | |
CA3088880A1 (en) | Bidirectional chef1 vectors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080044475.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10807224 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2771410 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010279294 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010807224 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20127005781 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2010279294 Country of ref document: AU Date of ref document: 20100806 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13390297 Country of ref document: US |